Flunitrazepam

Standard Drug Panel Inclusion

Flunitrazepam (Rohypnol) is detected on standard 10-panel drug screens and extended benzodiazepine panels, though its detection has historically been inconsistent. Older immunoassay platforms had poor cross-reactivity with 7-aminoflunitrazepam, the primary metabolite. In response to concerns about drug-facilitated sexual assault, manufacturers reformulated their assays to improve flunitrazepam detection, and current-generation immunoassays detect it with much greater reliability.

Urine Detection

Flunitrazepam and its metabolite 7-aminoflunitrazepam are detectable in urine for approximately 3 to 5 days after a single dose, with chronic users potentially testing positive for up to 2 weeks. The metabolite 7-aminoflunitrazepam is the primary target for both screening and confirmation. At therapeutic doses of 1 to 2 mg, urine concentrations may be low enough to approach the cutoff threshold of standard immunoassays, making hydrolysis and sensitive analytical methods important for reliable detection. In forensic cases involving suspected drug-facilitated crimes, laboratories often use lower cutoff values.

Blood and Serum Detection

Blood detection windows are 12 to 48 hours after ingestion. Therapeutic concentrations range from 5 to 15 ng/mL. Because flunitrazepam is active at very low doses, blood concentrations in assault cases may be extremely low, requiring analytical methods with sub-nanogram sensitivity.

Hair Follicle Detection

Hair analysis can detect flunitrazepam for up to 90 days and is particularly valuable in drug-facilitated assault investigations where delayed reporting makes urine testing impractical. Both flunitrazepam and 7-aminoflunitrazepam are targeted, with LC-MS/MS methods achieving limits of detection at 0.5 to 1 pg/mg of hair.

Confirmatory Methods

LC-MS/MS is the definitive confirmatory method for flunitrazepam, achieving limits of detection below 1 ng/mL in urine and below 0.5 ng/mL in blood. GC-MS with negative chemical ionization is an alternative that provides excellent sensitivity for this compound. Forensic laboratories typically use dedicated methods optimized for flunitrazepam given its significance in assault cases.

Reagent Testing

The Zimmermann reagent produces a yellow-green response with flunitrazepam. Mandelin yields an orange-brown color. These tests cannot distinguish it from other nitrobenzodiazepines. Immunoassay-based drink testing kits have been developed specifically to detect flunitrazepam in beverages, though their reliability varies.

Awareness of Context of Use

For individuals receiving or consuming substances in social settings: flunitrazepam and other sedating drugs can be covertly administered. Symptoms of covert drugging include sudden unexpected sedation, impaired speech and motor control, confusion, and memory gaps. If you or a friend experience these symptoms unexpectedly, move to a safe location and call for medical assistance.

Do Not Accept Open Drinks

Basic harm reduction for drug-facilitated assault situations: do not accept drinks you did not see poured from unopened containers, do not leave drinks unattended, and do not consume a drink that tastes unusual or bitter.

Standard Benzodiazepine Safety Applies

For those using flunitrazepam in other contexts: all standard benzodiazepine harm reduction applies — no combination with alcohol or opioids, accurate low-dose titration, avoidance of regular use, and gradual taper if dependence has developed.

Drug Testing

Drug testing strips for benzodiazepines can detect flunitrazepam in beverages. Fentanyl test strips are available separately. Both can be useful harm reduction tools in party or social settings.

Seek Medical Attention for Overdose

Suspected flunitrazepam overdose — profound sedation, respiratory depression, or unresponsiveness — warrants emergency medical attention. Flumazenil, the benzodiazepine antagonist, can reverse effects but has short duration and may require repeated dosing.

Anterograde Amnesia

Flunitrazepam's most clinically concerning property is its pronounced anterograde amnesia, which occurs at doses that do not necessarily produce unconsciousness. Individuals under flunitrazepam's influence may appear awake and coherent while subsequently having no memory of events. This combination underlies the drug's misuse in the context of sexual assault.

Respiratory Depression

Like all benzodiazepines, flunitrazepam produces dose-dependent respiratory depression, with synergistic risk when combined with alcohol or opioids. Its higher potency relative to diazepam means that smaller absolute doses can produce clinically significant respiratory depression.

Physical Dependence and Withdrawal

Regular flunitrazepam use produces physical dependence. Withdrawal syndrome is consistent with the benzodiazepine class — anxiety, insomnia, tremor, and risk of tonic-clonic seizures. The intermediate half-life produces withdrawal dynamics somewhere between short-acting compounds (more rapid, more acute) and ultra-long-acting compounds (slower onset, more prolonged).

Legal Risk

In the United States, possession of flunitrazepam (even without evidence of intent to use for assault) carries significant federal criminal penalties. The illegality of importation and possession creates additional legal risk for individuals obtaining it through illicit channels.

Interaction Profile

• Alcohol — Synergistic CNS depression; increases amnesia and respiratory depression risk substantially
• Opioids — High-risk combination
• Other CNS depressants — Additive effects

• International: Flunitrazepam is a Schedule III drug under the international Convention on Psychotropic Substances of 1971.

• Australia: Flunitrazepam is a Schedule 8 (S8) or controlled drug.

• Austria:** Flunitrazepam is legal for medical use under the AMG (Arzneimittelgesetz Österreich) and illegal when sold or possessed without a prescription under the SMG (Suchtmittelgesetz Österreich).

• Canada: Flunitrazepam is a Schedule I controlled substance and is available by prescription only.

• Germany: Since November 2011, flunitrazepam is controlled under Anlage 3 of the BtMG and requires a special prescription.

• Switzerland: Flunitrazepam is listed as a controlled narcotic substance, but it is also sparesly prescribed as a sleep aid in major cases. Flunitrazolam tablets only come in 1mg dosage and are dyed green and blue which colors one's mouth notably when ingested in a dissolved beverage.

• United Kingdom: Flunitrazepam is a Class C, Schedule 4 controlled drug under the Misuse of Drugs Regulations 2001.

• United States: Flunitrazepam is a Schedule IV drug under the Controlled Substances Act in the U.S but is not medically used.

• Responsible use

• Volumetric liquid dosing

• Psychoactive substance index

• Flunitrazolam

• Temazepam

• Benzodiazepines

• Depressants

• Flunitrazepam (Wikipedia)

• Flunitrazepam (Erowid Vault)

• Flunitrazepam (Isomer Design)

• Flunitrazepam (DrugBank)